According to Pfizer, grants will be awarded for research focusing on fostering a clearer understanding of cardiovascular risk-reduction strategies, such as educational programs, risk-assessment tools, screenings and clinical interventions.
Dr Lance Berman, senior medical director for Pfizer, said: “Pfizer is proud to partner with the European Foundation for the Study of Diabetes on this new research initiative. As part of our commitment to the care of patients with diabetes, Pfizer is dedicated to supporting research that will help identify ways to reduce these risks, further our understanding of optimal treatment options, and ultimately improve the lives of the people with diabetes.”